InflaRx N.V. (IFRX) Stock Analysis

InflaRx N.V. (IFRX) is a publicly traded company in the HEALTHCARE sector. It trades at $2.17, carries a market capitalization of $335.83M. This page summarizes the public market data, fundamentals, and frequently asked questions for IFRX, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $2.17
• Market Cap: $335.83M
• EPS: $-0.73
• 52-Week High: $2.95
• 52-Week Low: $0.74

Market Sentiment

InflaRx N.V. currently has a Bullish sentiment score of 0.17.

About InflaRx N.V.

InflaRx N.V. is a clinical-stage biopharmaceutical company focused on the development of novel C5a inhibitors targeting the complement system for the treatment of serious inflammatory and autoimmune diseases. Headquartered in Jena, Germany, with a strategic presence in the United States, the company is advancing its innovative therapeutic pipeline led by its candidate IFX-1, currently under evaluation for hidradenitis suppurativa and other indications. InflaRx's commitment to addressing unmet...

GNG Research Analysis

GNG Research scores InflaRx N.V. (IFRX) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for IFRX.

Frequently Asked Questions

Does IFRX pay dividends?

InflaRx N.V. (IFRX) does not currently pay a regular dividend.

What is IFRX's market cap?

InflaRx N.V. (IFRX) has a market capitalization of $335.83M with a current stock price of $2.17.